A single dose of a chromium-enriched glucomannan-fructo-oligosaccharide fiber complex significantly reduced postprandial ...

Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in emerging markets.

We have five products that will launch in the next 12-18 months. We recently launched Yesintek in the immunology space -- a ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.

ORLANDO -- Most adults with type 1 diabetes switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) needed to increase their dose of the inhaled product to achieve ...

The next wave, insulin analogs, began emerging in the mid-1990s. An insulin analog begins with genetically engineered human insulin, which is then modified to more closely resemble insulin ...

The therapy is still yet to be tested in chronic kidney disease patients, Hodgkinson added. Awiqli is a long-acting basal insulin analogue with a half-life of 196 hours (8.1 days). Its treatment ...

A study has found that two shots of insulin (basal insulin analog), though higher in dose, is marginally better than a single shot (premixed insulin) in lowering HbA1c (glycated haemoglobin).

Credit: Getty Images. Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death.

Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death. Treatment with analog rather ...

So, armed with the additional tailoring tools of genetic engineering, drug researchers began inventing insulin “analogs,” variations of the natural insulin protein, meant to supercharge performance.

The insulin and analogues market in India is presently worth Rs 3500 crore and we expect this to grow to a $1+ billion market opportunity in the next 5-6 years. Advt On the back of our market ...